2018: Verve Therapeutics founded with concept of one-time Rx to lower LDL as low as possible for as long as possible Today: we are announcing dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine 🙏 to patient volunteer $VERV globenewswire.com/news-release/2…

Someone got their liver gene edited for PCSK9 in New Zealand. Could lower bad blood cholesterol by 60%. First genetic therapy with a prevention angle. In the future, maybe, one-and-done editing at age 30 for all of us. End of clogged arteries? technologyreview.com/2022/07/12/105…

👇🏽 Heard on the Street from David Wainer Appreciate the opportunity to share the @VerveTx story The Wall Street Journal $VERV

Revolutionary Crispr gene editing speeds from lab to treatment room ft.com/content/e3c121…

Excited to announce today: development candidate for 2nd program (VERVE-201 targeting the ANGPTL3 gene) to treat homozygous FH as well as ASCVD data to be presented by Amit V. Khera European Society of Cardiology 2022 Press release: ir.vervetx.com/news-releases/… Data: ir.vervetx.com/static-files/3… $VERV

Delighted to announce a Clinical Trial Authorization (CTA) clearance by UK MHRA (Medicines and Healthcare products Regulatory Agency) for VERVE-101 as investigational Rx for patients with heterozygous familial hypercholesterolemia ir.vervetx.com/news-releases/… $VERV Verve Therapeutics

FH is the MOST COMMON morbid genetic condition and affects about 1 in 200 worldwide. It leads to lifelong high LDL-cholesterol and greatly increases the risk of #HeartDisease. #KnowFH

Today, we and ⁦⁦Rebecca Ganetzky⁩ report ⁦NEJM⁩ a remarkable case of twin boys with euthyroid hyper-metabolism (low body weight despite high caloric intake), due to a de novo mutation in mito CV that uncouples respiration from ATP synthesis. nejm.org/doi/full/10.10…

For @VerveTx targets, 2 criteria: human genetics & human pharmacology VERVE-201 targets ANGPTL3 Human genetics (L): complete deficiency ANGPTL3 = low blood lipids, no liver fat New human pharmacology (R): siRNA ArrowheadPharma, mimics human genetics! researchsquare.com/article/rs-209…

In Circulation, we publish today pre-clinical data for VERVE-101 Of note, American Heart Association tells us that for Scientific Sessions '22, this abstract the highest ranked one of all submitted from U.S. #AHA22 Press release: globenewswire.com/news-release/2… Paper: ahajournals.org/doi/10.1161/CI…

👇news Verve Therapeutics and Eli Lilly and Company establish global collaboration to advance an in vivo gene editing program targeting Lipoprotein(a) for the treatment of atherosclerotic cardiovascular disease ir.vervetx.com/news-releases/…

Thrilled to announce that U.S. FDA has cleared our *investigational new drug (IND)* application for VERVE-101 FDA reviewed our hold response which included: 1. interim clinical data from the ongoing heart-1 trial currently being conducted ex-U.S. 2. pre-clinical data to address

We are thrilled to gain Eli Lilly and Company as a new partner for @VerveTx PCSK9 & ANGPTL3 programs👇 Lilly has purchased from Beam Therapeutics all of their previously held product rights in PCSK9 & ANGPTL3 programs for a $600M total potential deal value. For the PCSK9 & ANGPTL3 product

Lilly pays $250M for Beam's opt-in rights to Verve's cardio genetic medicines - endpts.com/lilly-pays-250…

Can we precisely rewrite the genetic code - make a single DNA spelling change - in the liver of a human being for clinical effect? YES! Scientific milestone: VERVE-101 provides first proof-of-concept for in vivo DNA base editing in humans Clinical implication: It’s early

In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients statnews.com/2023/11/12/in-… via STAT

Glad to announce the dosing of the first patient with VERVE-102 in the Heart-2 clinical trial VERVE-102: *in vivo base editor to permanently turn off the PCSK9 gene in liver and durably lower blood LDL-C *delivered using Verve Therapeutics proprietary GalNAc-LNP delivery system as a

@VerveTx 3Q earnings: 1. VERVE-102 targeting PCSK9 being tested in Heart-2 trial *treated 7 patients now across 2 dose levels (0.3 mg/kg and 0.45 mg/kg) *well tolerated, no serious adverse events, no clinically significant lab abnormalities *escalation to next dose after

x.com/i/article/1904…

We are hiring! Delighted to share an opportunity to join the clinical development team at Verve Therapeutics Eli Lilly and Company , where we are on a mission to transform the care of ASCVD through single-course gene editing medicines! Apply here: lnkd.in/eVDDP85i